CD46 Shedding as a Biomarker for Liver Stress
Author Information
Author(s): Paul Kupke, Jordi Yang Zhou, Gunther Glehr, Paloma Riquelme, Lena Scheibert, Akinbami Adenugba, Hans J. Schlitt, Edward K. Geissler, Jens M. Werner, James A. Hutchinson
Primary Institution: University Hospital Regensburg
Hypothesis
Can soluble CD46 (sCD46) serve as a sensitive biomarker for early liver stress in various liver diseases?
Conclusion
sCD46 is a promising biomarker for detecting early liver diseases and monitoring therapeutic responses.
Supporting Evidence
- sCD46 levels were significantly higher in steatotic patients compared to non-steatotic patients.
- Prostaglandin E2 treatment increased sCD46 release in fat-loaded HepaRG cells.
- Hepatitis E virus infection led to increased sCD46 release from HepaRG cells.
- Drug exposure to certain cytostatic compounds increased sCD46 levels in HepaRG cell supernatants.
Takeaway
Scientists found that a protein called sCD46 can help doctors see if the liver is stressed or sick, even before other tests show problems.
Methodology
The study developed and validated an ELISA to measure sCD46 levels in human plasma and serum, analyzing its release under various stress conditions.
Potential Biases
Potential bias due to the study being conducted at a single center.
Limitations
The kinetics of sCD46 release and its degradation were not assessed, which is important for its interpretation as a clinical biomarker.
Participant Demographics
Included 158 patients undergoing liver tumor resection and 42 patients with chronic hepatitis C.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI [93.5, 100]
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website